EUROCASTLE INVESTMENT LTD (ECT.AS) Fundamental Analysis & Valuation

AMS:ECT • GB00B94QM994

Current stock price

11.8 EUR
-0.1 (-0.84%)
Last:

This ECT.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ECT.AS Profitability Analysis

1.1 Basic Checks

  • In the past year ECT has reported negative net income.
  • In the past year ECT has reported a negative cash flow from operations.
  • In multiple years ECT reported negative net income over the last 5 years.
  • In the past 5 years ECT always reported negative operating cash flow.
ECT.AS Yearly Net Income VS EBIT VS OCF VS FCFECT.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

  • ECT has a Return On Assets of -1.66%. This is in the lower half of the industry: ECT underperforms 60.87% of its industry peers.
  • ECT's Return On Equity of -1.74% is in line compared to the rest of the industry. ECT outperforms 44.93% of its industry peers.
Industry RankSector Rank
ROA -1.66%
ROE -1.74%
ROIC N/A
ROA(3y)-1.72%
ROA(5y)-1.28%
ROE(3y)-1.77%
ROE(5y)-1.34%
ROIC(3y)N/A
ROIC(5y)N/A
ECT.AS Yearly ROA, ROE, ROICECT.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

1.3 Margins

  • In the last couple of years the Profit Margin of ECT has remained more or less at the same level.
  • In the last couple of years the Operating Margin of ECT has remained more or less at the same level.
  • ECT's Gross Margin of 34.12% is in line compared to the rest of the industry. ECT outperforms 47.83% of its industry peers.
  • In the last couple of years the Gross Margin of ECT has grown nicely.
  • The Profit Margin and Operating Margin are not available for ECT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.12%
OM growth 3Y-7.21%
OM growth 5Y-1.26%
PM growth 3Y-7.21%
PM growth 5Y-1.2%
GM growth 3Y-0.87%
GM growth 5Y19.91%
ECT.AS Yearly Profit, Operating, Gross MarginsECT.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ECT.AS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ECT has been increased compared to 1 year ago.
  • ECT has less shares outstanding than it did 5 years ago.
  • ECT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ECT.AS Yearly Shares OutstandingECT.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ECT.AS Yearly Total Debt VS Total AssetsECT.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -92.57, we must say that ECT is in the distress zone and has some risk of bankruptcy.
  • ECT has a worse Altman-Z score (-92.57) than 84.06% of its industry peers.
  • There is no outstanding debt for ECT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -92.57
ROIC/WACCN/A
WACCN/A
ECT.AS Yearly LT Debt VS Equity VS FCFECT.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • ECT has a Current Ratio of 15.66. This indicates that ECT is financially healthy and has no problem in meeting its short term obligations.
  • ECT's Current ratio of 15.66 is amongst the best of the industry. ECT outperforms 100.00% of its industry peers.
  • ECT has a Quick Ratio of 15.66. This indicates that ECT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ECT (15.66) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 15.66
Quick Ratio 15.66
ECT.AS Yearly Current Assets VS Current LiabilitesECT.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ECT.AS Growth Analysis

3.1 Past

  • ECT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.75%.
  • ECT shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -2.08% yearly.
  • The Revenue has grown by 75.76% in the past year. This is a very strong growth!
  • ECT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.85% yearly.
EPS 1Y (TTM)0.75%
EPS 3Y-15.5%
EPS 5Y-2.08%
EPS Q2Q%-478.22%
Revenue 1Y (TTM)75.76%
Revenue growth 3Y-25.89%
Revenue growth 5Y-52.85%
Sales Q2Q%-28.66%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECT.AS Yearly Revenue VS EstimatesECT.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M
ECT.AS Yearly EPS VS EstimatesECT.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. ECT.AS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ECT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ECT.AS Price Earnings VS Forward Price EarningsECT.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ECT.AS Per share dataECT.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ECT.AS Dividend Analysis

5.1 Amount

  • ECT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ECT.AS Fundamentals: All Metrics, Ratios and Statistics

EUROCASTLE INVESTMENT LTD

AMS:ECT (4/16/2026, 7:00:00 PM)

11.8

-0.1 (-0.84%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)N/A
Earnings (Next)04-22
Inst Owners5.78%
Inst Owner ChangeN/A
Ins Owners3.05%
Ins Owner ChangeN/A
Market Cap11.80M
Revenue(TTM)1.10M
Net Income(TTM)-369.00K
Analysts84
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.71
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS1.1
BVpS21.22
TBVpS21.22
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -1.66%
ROE -1.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.12%
FCFM N/A
ROA(3y)-1.72%
ROA(5y)-1.28%
ROE(3y)-1.77%
ROE(5y)-1.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-7.21%
OM growth 5Y-1.26%
PM growth 3Y-7.21%
PM growth 5Y-1.2%
GM growth 3Y-0.87%
GM growth 5Y19.91%
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.66
Quick Ratio 15.66
Altman-Z -92.57
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.75%
EPS 3Y-15.5%
EPS 5Y-2.08%
EPS Q2Q%-478.22%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)75.76%
Revenue growth 3Y-25.89%
Revenue growth 5Y-52.85%
Sales Q2Q%-28.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.54%
EBIT growth 3Y-31.23%
EBIT growth 5Y-53.45%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-219.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-219.08%
OCF growth 3YN/A
OCF growth 5YN/A

EUROCASTLE INVESTMENT LTD / ECT.AS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EUROCASTLE INVESTMENT LTD?

ChartMill assigns a fundamental rating of 3 / 10 to ECT.AS.


What is the valuation status for ECT stock?

ChartMill assigns a valuation rating of 0 / 10 to EUROCASTLE INVESTMENT LTD (ECT.AS). This can be considered as Overvalued.


Can you provide the profitability details for EUROCASTLE INVESTMENT LTD?

EUROCASTLE INVESTMENT LTD (ECT.AS) has a profitability rating of 2 / 10.


Can you provide the financial health for ECT stock?

The financial health rating of EUROCASTLE INVESTMENT LTD (ECT.AS) is 7 / 10.